TrialClinical pharmacology and therapeutics2025

Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.

Roger S McIntyre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.